J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swan, S. K.
Right arrow Articles by Skobieranda, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swan, S. K.
Right arrow Articles by Skobieranda, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACOKINETICS

Pharmacokinetic Profile of Rizatriptan 10-mg Tablet and 10-mg Orally Disintegrating Tablet Administered With or Without Water in Healthy Subjects: An Open-Label, Randomized, Single-Dose, 3-Period Crossover Study

Suzanne K. Swan, MD, Harry Alcorn, Jr, PharmD, Anthony Rodgers, MS, Carolyn M. Hustad, PhD, Karen E. Ramsey, RPh, Susan Woll, MBA and Franck Skobieranda, MD

From DaVita Clinical Research, Minneapolis, Minnesota (Dr Swan, Dr Alcorn); Hennepin County Medical Center, Minneapolis, Minnesota (Dr Swan); and Merck & Co, Inc, West Point, Pennsylvania (Mr Rodgers, Dr Hustad, Ms Ramsey, Ms Woll, and Dr Skobieranda).

This open-label, 3-period crossover study compared the plasma concentration profiles of rizatriptan tablet, orally disintegrating tablet with water (ODTc), and ODT without water (ODTs) in 24 healthy volunteers aged 18 to 45 years. At each period, subjects received a single dose of either 10-mg rizatriptan tablet, 10-mg rizatriptan ODTs, or 10-mg rizatriptan ODTc. The authors hypothesized that ODTc has a greater geometric mean AUC0-2h than ODTs and that ODTc has a greater geometric mean AUC0-1h than tablet. A secondary end point was to compare the time of occurrence of the maximum rizatriptan plasma concentration (tmax) of each dosing method. ODTc had a statistically significantly greater geometric mean AUC0-2h compared with ODTs (33.84 h·ng/mL vs 18.83 h·ng/mL; P < .001). ODTc had a slightly, but not statistically significantly, greater geometric mean AUC0-1h compared with rizatriptan tablet (17.07 h·ng/mL vs 13.32 h·ng/mL). The median tmax was 0.67 hours for ODTc and tablet and 1.33 hours for ODTs. ODTc showed a slightly, but not significantly, faster rate of absorption compared with tablet. ODTs with water had a faster rate of absorption than ODTc. Future studies are needed to determine whether this pharmacokinetic difference produces differential efficacy in a clinical setting.

Key Words: Rizatriptan • pharmacokinetics • clinical trial • migraine medication

Address for reprints: Franck Skobieranda, MD, Merck & Co, Inc, PO Box 4, HM-323, West Point, PA 19486.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology